UPDATE: Cowen Starts Aadi Bioscience Inc (AADI) at Outperform

Cowen analyst Boris Peaker initiates coverage on Aadi Bioscience Inc (NASDAQ: AADI) with a Outperform rating.

The analyst comments "We are initiating coverage on Aadi with an Outperform rating without a price target. Aadi is a late clinical stage biotech company developing a nab formulation of sirolimus (Fyarro/ABI-009) for use in the rare tumor PEComa and tumors harboring TSC1/2 mutations. With a PUDFA date in November 2021 for PEComa and near term initiation of a tumor agnostic pivotal trial, we see upside to the stock."

For an analyst ratings summary and ratings history on Aadi Bioscience Inc click here. For more ratings news on Aadi Bioscience Inc click here.

Shares of Aadi Bioscience Inc closed at $29.37 yesterday.

You May Also Be Interested In

• Goldman Sachs Upgrades Plains GP Holdings, L.P (PAGP) to Neutral
• UBS Double Upgrades China Resources Power Holdings (836:HK) (CRPJY) to Buy
• JPMorgan Starts Arashi Vision Inc (688775:CH) at Neutral